Proposed sale of controlling stake to US private equity group has sparked backlash in country
US private equity group nears deal for pharma spin-off after edging out PAI-led consortium
Interest of PE groups in Sanofi’s Opella highlights the renewed ebullience of debt financiers
The deal is expected to be one of Europe’s largest this year as EU IPO market shows signs of recovery
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Paul Hudson needs to convince investors that pharma group’s new blockbuster drugs will be successful
Paul Hudson is meeting investors to explain multibillion-euro push to get drug candidates to market
Preliminary probe looks into financial communications around 2017 launch of group’s blockbuster drug Dupixent
French pharma group announces consumer unit split and increased R&D investment
French pharma group needs new assets after trial failure of cancer treatment amcenestrant
Chief executive Paul Hudson sounds the alarm over British government’s cuts to research
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
Change comes as French pharma group pours money into immunology and cancer research
Shares in French pharma group tumble nearly 6% after blow to pipeline of new treatments
Companies face thousands of pending personal injury cases linking Zantac to cancer
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
‘Next-generation’ jab delivers strong immune response against variants
Cross-section of companies want to ‘ensure laggards don’t delay the market shift’
Drugmakers to apply for protein-based shot to be used as primary and booster jabs
French pharma group still working on long-delayed Covid vaccine
French pharma group says jab will probably come to market in first quarter of 2022
French group says it is too late to market jab and is working on another with GSK using different technique
The acquisition is a sign of the French pharma group’s determination to get back on the podium
